The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
I find it unfathomable that Richard is standing back and has zero to report to uplift our spirits. Suck a long sustained amount of time with nothing can mean only something - it’s certainly not a dead donkey or key players would have dropped out long ago- something is going on and that’s a fact but Richard really needs to think about the little people here - unless he’s going into the cardio vascular business and wants to test out dodgy tickers !
But wouldn’t that information that TFG get ( if of substance) need to be an RNS ?
That’s the game right ? ….. the rules.
I’m chucking a dart at a Thursday update … no idea why , I just like Thursdays and there’s a significant date approaching.
Dear Mr xxxxxxxxxx,
I understand you have left a few messages for me seeking a company update. Apologies for not responding sooner.
Richard provided an update by way of a LinkedIn post last month summarising progress from last year and restating the company’s focus. In case you missed it, you can find it here.
We are working to maximise the potential value of SNG001 through a clinical development programme designed to secure a regulatory approval and a commercialisation pathway into the US, European and other major markets as quickly as possible. While the post hoc analyses of the Phase 3 SPRINTER trial provide important insights on where SNG001 may well be having a beneficial effect in certain patient groups, I’m sure you are aware that a post hoc analysis is not sufficient for a regulatory submission.
The accumulated non-clinical and clinical data has strengthened our conviction that SNG001 has potential as a broad-spectrum antiviral which could be directed towards patients infected with a wide range of viruses including influenza, RSV, coronaviruses, parainfluenza viruses and others.
As it stands today, there are no broad-spectrum antivirals approved for use in patients with severe viral lung infections who are at increased risk of progressing to severe disease or death, and this is in the context of more than 3 million people a year being hospitalised due to these infections in the US alone. It is then perhaps not surprising that this also means there is no precedent for a broad-spectrum antiviral clinical development programme. Designing and determining a clinical pathway for this approach is complex, as there are multiple viruses being targeted for different high-risk patient groups.
We believe that SNG001 could be a very valuable broad-spectrum antiviral so continue to actively pursue and refine multiple clinical approaches including company- and investigator-sponsored studies and possibly platform studies (as and when appropriate), to confirm the most expeditious clinical development path for SNG001.
As such, we continue our focus our discussions with investigators, regulatory authorities, the pharmaceutical and biotech industry, platform trial organisers, NGOs and government bodies to identify and establish the optimal method of conducting further trials to provide us with the evidence we need for a regulatory submission.
We cannot provide a more detailed timeline at this stage and aren’t disclosing the specifics of these discussions and applications with specific trials. Of course, as soon as we have a concrete trial or trials agreed, we will make an announcement. I appreciate this may not be the level of detail you are seeking; we will provide further information as soon as we are able.
Best wishes,
Brooke
Small but important detail- why is there a specific cost in dollars at the bottom of this screen ?
https://www.synairgen.com/
Anyone else ****ting them selves?
I am happy to be proven wrong, I have a feeling that if there is nothing that transpires from this week, the market will see it as (we have been given a barrel of fish to shoot and missed everyone) every big boy pharmacy representative in one place and we could hook a duck! This will tank ….
As you know I am never pessimistic but that worries me.